Aidence was founded in Amsterdam in 2015. It aims to improve medical diagnostics by applying Deep Learning to medical image analysis to bring the full potential of Artificial Intelligence into the hands of medical professionals in medical imaging and disease detection. Aidence's AI-enabled pulmonary nodule management assistant, Veye Chest, connects with existing imaging infrastructure and enables radiologists to better spot and track changes in pulmonary nodules and thus increases the potential to detect lung cancer.

With its practical AI solution for radiologists, Aidence fits very well with our ambition to contribute to improving the healthcare ecosystem and ultimately retaining affordable healthcare for all.

With the investment, Aidence will continue building its European market expansion while also building towards FDA clearance giving access to the US healthcare market. This investment will allow our research and development team to expand and explore new avenues for the Veye platform to support our radiologist AI pioneers and the patients they care for.

Start investment
2019

We’ve been determined since day one to deliver a tangible clinical AI solution that can be used by healthcare professionals to help their patients. We welcome INKEF and RCI on our journey as we strive to shape the future of the medical imaging industry.

Mark-Jan Harte

CEO

Contact us

Address

Rabo Corporate Investments

Croeselaan 28

3521 CB Utrecht